Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic Malignancies

No abstract is available for this paper.

• Publication year

  2009

• Venue

  International Journal of Gynecologic Cancer

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/IGC.0b013e3181a1bf2ePMID 19407575
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions

  2007cited by this paper
• Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.

  2007cited by this paper
• Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.

  2007influential reference
• The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.

  2007cited by this paper
• A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer

  2007cited by this paper
• Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.

  2006cited by this paper
• Carboplatin hypersensitivity induced by low‐dose paclitaxel/carboplatin in multiple platinum‐treated patients with recurrent ovarian cancer

  2005cited by this paper
• Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.

  2005cited by this paper
• Carboplatin Hypersensitivity Reactions: A Single Institution Experience

  2005cited by this paper
• Successful carboplatin desensitization in patients with proven carboplatin allergy

  2005cited by this paper
• Carboplatin desensitization.

  2004cited by this paper
• Carboplatin hypersensitivity

  2004cited by this paper
• Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube

  2004cited by this paper
• Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.

  2004cited by this paper
• Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity

  2004cited by this paper
• Cisplatin may be a Valid Alternative Approach in Ovarian Carcinoma with Carboplatin Hypersensitivity. Report of Three Cases

  2003cited by this paper
• Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions

  2003cited by this paper
• Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.

  2003cited by this paper
• Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity.

  2003cited by this paper
• Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.

  2003cited by this paper
• A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.

  2003cited by this paper
• Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.

  2003cited by this paper
• Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

  2002cited by this paper
• Hypersensitivity reactions to carboplatin.

  2002cited by this paper
• Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin.

  2002cited by this paper
• Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.

  2001cited by this paper
• Hypersensitivity Reactions to Carboplatin Administration Are Common but Not Always Severe: A 10-Year Experience

  2001cited by this paper
• Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.

  2001cited by this paper
• Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.

  2001cited by this paper
• Hypersensitivity Reaction to Carboplatin during Treatment for Ovarian Cancer: Successful Resolution by Replacement with Cisplatin

  1999cited by this paper
• Clinical features of hypersensitivity reactions to carboplatin.

  1999influential reference
• Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma

  1998cited by this paper
• A modified, prolonged desensitization protocol in carboplatin allergy.

  1996cited by this paper
• Hypersensitivity reactions to carboplatin. Report of two patients, review of the literature, and discussion of diagnostic procedures and management

  1994cited by this paper
• Anaphylaxis to carboplatin--a new platinum chemotherapeutic agent.

  1992cited by this paper
• Hypersensitivity reactions to carboplatin.

  1991cited by this paper
• Report of Three Cases

  1962cited by this paper

• Development and evaluation of a new protocol for the management of immediate hypersensitivity reactions in an oncology outpatient department.

  2025cites this paper
• Rapid drug desensitization with chemotherapy: when should omalizumab be considered?

  2025cites this paper
• Risk factors of Hypersensitivity Reactions to Carboplatin: A Systematic Review and Meta-analysis.

  2024cites this paper
• Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)

  2024cites this paper
• Management of infusion-related reactions in cancer therapy: strategies and challenges

  2024cites this paper
• Characteristics of patients with hypersensitivity reactions to chemotherapeutic and biological agents and desensitization behavior

  2023cites this paper
• Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers

  2023cites this paper
• Pearls for practice from the 2022 joint task force drug allergy practice parameter

  2023cites this paper
• Drug Allergy: A 2022 Practice Parameter Update.

  2022cites this paper
• Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer

  2022cites this paper
• Reacciones de hipersensibilidad a quimioterapéuticos y biológicos

  2022cites this paper
• Carboplatin

  2021cites this paper
• Hypersensitivity Reactions to Platinum Agents and Taxanes

  2021cites this paper
• Hypersensitivity reactions to chemotherapy: an EAACI Position Paper

  2021cites this paper
• Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization.

  2021cites this paper
• Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin.

  2020cites this paper
• HIPEC with cisplatin in a patient with a prior hypersensitivity reaction to systemic oxaliplatin

  2020cites this paper
• Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin

  2019cites this paper
• Desensitization for Allergic Reactions to Chemotherapy

  2019cites this paper
• Analysis and treatment of 45 platinum-allergic gynecologic malignant tumors

  2018cites this paper
• Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer

  2018cites this paper
• Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer.

  2018cites this paper
• Retrospective evaluation of a rechallenge protocol in patients experiencing hypersensitivity reactions with prior chemotherapy in a tertiary hospital

  2018cites this paper
• Options in Hypersensitivity Reactions to Chemotherapeutics

  2018cites this paper
• A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer

  2018cites this paper
• Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report

  2017cites this paper
• Platinum Chemotherapy Hypersensitivity: Prevalence and Management.

  2017cites this paper
• Comparison of Hypersensitivity Reactions to Carboplatin Retreatment in Gynecologic Cancer Patients between One and Two Hour Infusions: a Randomized Trial Study

  2017cites this paper
• Immediate Hypersensitivity Reaction to Chemotherapeutic Agents.

  2017cites this paper
• Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies

  2017influential citation
• Immediate Drug Hypersensitivity

  2016cites this paper
• Oxaliplatin Is a Safe Alternative Option for Patients With Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin

  2015cites this paper
• Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions.

  2015cites this paper
• Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin

  2013cites this paper
• Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions

  2013cites this paper
• Possible anaphylaxis to palonoestron

  2012cites this paper
• Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer.

  2012cites this paper
• Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers

  2011cites this paper
• Examination of Expression Mechanism and Risk Factors of Cancer Chemotherapy-induced Adverse Reactions

  2011cites this paper
• Drug-induced urticaria: causes and clinical courses.

  2011cites this paper
• Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

  2011cites this paper
• Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer.

  2010cites this paper
• ERRATUM

  2009cites this paper
• ERRATUM

  2009cites this paper
• ERRATUM

  2009cites this paper